Terapeutisk middel til meibomsk dysfunktion
The present invention relates to a pharmaceutical composition comprising sirolimus at a concentration of 0.01 to 0.5% (w/v) as a sole active ingredient for use in the suppression of obstruction of meibomian gland and/or telangiectasia around meibomian gland orifices, wherein the composition is admin...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Patent |
| Sprache: | dan |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Zusammenfassung: | The present invention relates to a pharmaceutical composition comprising sirolimus at a concentration of 0.01 to 0.5% (w/v) as a sole active ingredient for use in the suppression of obstruction of meibomian gland and/or telangiectasia around meibomian gland orifices, wherein the composition is administered to the eyelid skin 1 to 2 times per a day. |
|---|